The vaccine by US company Moderna, the keenly awaited one by the entire world, could be ready by the end of this year, according to the company CEO.
In a media interaction, company CEO Stéphane Bancel said that the vaccine could be ready approval by the Food and Drug Administration (FDA) by the end of this year.
“It is possible — assuming a best-case scenario and there are many risks that could derail us, obviously — but we could potentially be in a position to file to the FDA toward the end of the year or early next year,” Stéphane Bancel said on Fox Business’s “Mornings with Maria.”
The company has raised the hopes around the world after its early data from a phase one clinical trial showed that people given a potential vaccine generated an immune response similar to one in people who had recovered from the disease. Additionally, company’s potential vaccine was successful in preventing the virus from replicating in mice’s lungs in another study, it said.
The company is working with the National Institute of Allergy and Infectious Diseases, led by Anthony Fauci and will soon begin a phase two trial and said it hopes to begin a phase three trial in July.
Bancel has said that manufacturing of the vaccine could start as early as July, even before trials are complete, through a partnership with the Swiss biotech company Lonza.